A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors - 30/09/09
pages | 5 |
Iconographies | 0 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Objective |
To obtain an optimal premedication protocol for paclitaxel liposome (Lipusu®) in the treatment of solid tumors.
Methods |
From February 2005 to September 2007, 53 patients with advanced non-small-cell lung cancer (16 cases), breast cancer (14 cases), esophagus cancer (six cases), gastric cancer (16 cases), head and neck cancer (one case) were recruited from the Department of Chemotherapy, Jiangsu Cancer Hospital and Research Institute. Lipusu was delivered at 175mg/m2 (triweekly or divided into weekly) as a component of combined chemotherapy. Several premedications were attempted (detailed in the text).
Results |
The toxicity profile of premedications included: insomnia (five cases), dysphoria (three cases), hyperglycemia (two cases), fatigue (two cases), abdominal distension (one case), and vertigo (one case). No treatment-related death occurred.
Conclusions |
Our recommendations for the premedication of Lipusu in the treatment of solid tumors are: (1) methylprednisolone 40mg, administered intravenously 30min before Lipusu, and granisetron 30min before chemotherapy, (2) dexamethasone 2.25–3mg taken orally 12h and 2h before Lipusu, and granisetron 30min before chemotherapy.
Le texte complet de cet article est disponible en PDF.Keywords : Solid tumor, Lipusu, Premedication
Plan
Vol 63 - N° 8
P. 603-607 - septembre 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?